Ausgabe 5/2007
Inhalt (16 Artikel)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang, Jalila Adnane, Pamela A. Trail, Joan Levy, Arris Henderson, Dahai Xue, Elizabeth Bortolon, Marina Ichetovkin, Charles Chen, Angela McNabola, Dean Wilkie, Christopher A. Carter, Ian C. A. Taylor, Mark Lynch, Scott Wilhelm
Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma
Takenori Niioka, Tsukasa Uno, Norio Yasui-Furukori, Takenori Takahata, Mikiko Shimizu, Kazunobu Sugawara, Tomonori Tateishi
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
Tomasz M. Beer, Milind M. Javle, Christopher W. Ryan, Mark Garzotto, Gilbert N. Lam, Alvin Wong, W. David Henner, Candace S. Johnson, Donald L. Trump
In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng
Wei Wang, Yuqing Zhao, Elizabeth R. Rayburn, Donald L. Hill, Hui Wang, Ruiwen Zhang
Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster
R. F. C. Leitão, R. A. Ribeiro, E. A. L. Bellaguarda, F. D. B. Macedo, L. R. Silva, R. B. Oriá, M. L. Vale, F. Q. Cunha, G. A. C. Brito
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study
Daniele Santini, Bruno Vincenzi, Gaia Schiavon, Marisa Di Seri, Vladimir Virzí, Bruno Spalletta, Marco Caricato, Roberto Coppola, Giuseppe Tonini
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
Rosalyn Juergens, Julie Brahmer, David Ettinger
A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer
Takuo Hara, Kenji Omura, Makoto Hirano, Yasuyuki Asada, Yoshinori Munemoto, Junichi Sakamoto
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta, Laura Catena, Giuseppe Procopio, Sara De Dosso, Ettore Bichisao, Leonardo Ferrari, Antonia Martinetti, Marco Platania, Elena Verzoni, Barbara Formisano, Roberto Bajetta
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis
Marcos Venício Alves Lima, Francisco Valdeci Ferreira, Francisco Yuri Bulcão Macedo, Gerly Anne de Castro Brito, Ronaldo Albuquerque Ribeiro
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
Jianping Chen, Melissa Smith, Kenneth Kolinsky, Violeta Adames, Nila Mehta, Luke Fritzky, Mohammad Rashed, Eric Wheeldon, Michael Linn, Brian Higgins
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours
Johnson J. Liu, Lai-Ming Ching, Michael Goldthorpe, Rachel Sutherland, Bruce C. Baguley, James A. Kirker, Mark J. McKeage
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
Alan P. Brown, Tage C. G. Carlson, Cho-Ming Loi, Michael J. Graziano
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial
M. B. Jameson, B. C. Baguley, P. Kestell, L. Zhao, J. W. Paxton, P. I. Thompson, S. Waller
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors
M. Campone, N. Isambert, E. Bourbouloux, S. Maury, P. Monin-Baroille, J. Berille, P. Fumoleau
Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas
Bih Fang Pan, J. Arly Nelson